Non-Hodgkin's lymphoma or NHL is a serious affection which occurs due to the presence of B cells (B lymophocytes), a type of white blood cells which usually lead to severe complications such as tumors. Even though, treatments with chemotherapy and radiation are considered effective for many people who suffer from NHL, on the other hand for many pantients these procedures can be very toxic.
In addition to this, specialists have developed in the laboratories a new theraphy to treat NHL, a theraphy known as Monoclonal-antibody which has been proved to be safe and effective for certain patients. As we know the body produces antibodies, substances which have the role to fight against bacteria and viruses. Moreover, monoclonal antibodies have been produced in laboratories like many other antibodies and have the role in producing anti-tumor effects. Since most NHL patients have B cells, treatment with monoclonal-antibodies has brought important results in healing lymphoma and much more they have been prescribed with other toxin or radioactive particles that usually kill cells.
Furthermore, monoclonal antibody treatments usually include medications as Rituxan or Bexxar. First of all, treatments with Rituxan are considered very effective for people who suffer from NHL and may be used for other types of lymphomas too. Rituxan is the only monoclonal antibody treatment approved for NHL and most of the time has been studied in patients that have relapsed low grade NHL. Moreover, it can be taken without other medicines and it is usually given intravenously once a week for 4 weeks. In contrast to other procedures, Rituxin doesn't offer serious side effects such as hair loss, vomiting, and low blood counts.
Secondly, another monoclonal antibody which is being tested in laboratories is Bexxar. This medicine is a murine monoclonal antibody and doesn't have a naked form due to the presence of a radiocative iodine molecule which is attached to it. Just like Rituxan, this agent is administered intravenous with the first dose having a trace amount of radioactivity and the second dose containing most of the radioactive iodine. On the other hand, Bexxar has some negative aspects, such as fever, chills or shakes and in some cases NHL patients may have temporary drop in blood counts.
Thirdly, another monoclonal antibody which has been studied as NHL treatments is Oncolym. This agent has been studied in a radiolabeled form like Bexxar and has proved to be toxic like other radiolabeled antibodies. In contrast, LL2 is a humanized antibody, using a naked, unlabeled form as well as a radiolabeled form.
To conclude, monoclonal antibodies can be very effective in treating NHL due to their low toxicity and also the advantage of combining them with each other and also by using them in combination with chemotherapy or other procedures. It is important to say that people who suffer from NHL should be aware of their condition and become well-informed in order to follow the suitable treatment.
At first patients develop cutaneous Tcell lymphoma which starts on and in the skin, due to the suppressed immune system after which Sezary syndrome appears. Mycosis Fungoides is one of the cutaneous Tcell lymphoma forms that progress slowly after which there may appear Sezary syndrome which is a leukemic variant of mycosis fungoides manifested with swollen lymph nodes and a large number of abnormal cells circulating in the blood. We must clearly differentiate cutaneous Tcell lymphoma from peripheral T-cell lymphomas or adult T-cell lymphoma/leukemia which appear on the skin but are more severe and have a different treatment.
Diagnosis
To have a certain diagnosis you'll be taken a biopsy which is a surgical removal of suspect tissue and which will be tested correspondingly by a pathologists to have a clear view over the type of the cancer and how far it is spread (known as staging). Cutaneous Tcell lymphoma is very different from other types of Non-Hodgkin's lymphoma. The cancer's spread on the skin is characterized from T1 to T4, from the staging of involvement of the lymph node N0 toN3 and whether there are distant metastasis M1 to M0. The cause of cutaneous Tcell lymphoma is unknown, viral cause has been suspected. Cutaneous Tcell lymphoma is a rare disease, with an annual incidence of about .29 cases per 100,000 persons in the United States. It is more common in Eastern Europe. The symptoms of cutaneous Tcell lymphoma are seen primarily in the skin, with itchy red patches or plaques and, usually over time, mushroom-shaped skin tumors. Diagnosis of cutaneous Tcell lymphoma is often difficult in the early stages because of its slow progression and ability to mimic many other benign skin conditions. The early stages of cutaneous Tcell lymphoma resemble closely the rashes of eczema, psoriasis, and contact dermatitis. The only universal symptom of the disease is the itch.
Treatment
Combination of treatments has been proved to be inneficient, but there are several treatments considering the stages: chemotherapy on the skin and ultraviolet A light exposure if the disease is in early stages and total skin electron beam radiation if the disease is spread. There are indicated several tests to support the treatment and the diagnosis so the patient should stay informed regarding the disease and the most recent discoveries in what concerns the treatment. Many important issues remain including the best dosing and schedules of administration. Potential strategies are being explored such as boosting the immune system to increase the effects of antibody treatment. Given the promising, but as yet unclear, current situation, it is important that patients review the options for their individual condition, become well-informed, and consider participation in clinical trials to have access to the broadest range of treatments.
Groshan Fabiola has sinced written about articles on various topics from Woman Menopause, Medical Condition and Health. So, if you want to find out more about or even about. Groshan Fabiola's top article generates over 6120000 views. to your Favourites.